As an expansion of its autoimmune efforts, the Company also announced that it plans to file an Investigational New Drug or IND application to begin the clinical development of IGM-2644, its CD38 x CD3 T cell engager antibody, for the treatment of autoimmune diseases. As part of its strategic refocus, the Company is halting all hematologic oncology clinical development as well as the clinical development of its targeted cytokine product candidate. The Company is prioritizing the clinical development of IGM-2644, a CD38 x CD3 T cell engager antibody, in the treatment of autoimmune diseases, and it plans to file an IND for these purposes in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IGMS:
- IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
- IGM Biosciences price target lowered to $11 from $17 at H.C. Wainwright
- IGM Biosciences price target lowered to $16 from $19 at Wedbush
- IGM Biosciences price target lowered to $25 from $26 at Stifel
- IGM Biosciences price target lowered to $8 from $11 at RBC Capital
